Squarepoint
SNDX icon

Squarepoint’s Syndax Pharmaceuticals SNDX Stock Holding History

Squarepoint’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.1M Buy
370,317
+188,765
+104% +$3.93M 0.01% 1243
2026
Q1 		$4.24M Buy
181,552
+161,738
+816% +$3.51M 0.01% 1624
2025
Q4 		$416K Sell
19,814
-15,705
-44% -$274K ﹤0.01% 3351
2025
Q3 		$546K Sell
35,519
-1,738
-5% -$22.7K ﹤0.01% 3165
2025
Q2 		$349K Buy
+37,257
New +$410K ﹤0.01% 3570
2024
Q1 		– Sell
-52,035
Closed -$1.12M – 4572
2023
Q4 		$1.12M Buy
52,035
+22,915
+79% +$352K ﹤0.01% 2444
2023
Q3 		$423K Sell
29,120
-10,163
-26% -$192K ﹤0.01% 2920
2023
Q2 		$822K Buy
+39,283
New +$818K ﹤0.01% 2314
2021
Q3 		– Sell
-32,575
Closed -$559K – 3390
2021
Q2 		$559K Buy
32,575
+5,936
+22% +$109K ﹤0.01% 2046
2021
Q1 		$596K Sell
26,639
-64,488
-71% -$1.46M ﹤0.01% 1889
2020
Q4 		$2.03M Buy
91,127
+25,643
+39% +$532K 0.02% 936
2020
Q3 		$967K Buy
65,484
+45,171
+222% +$689K 0.01% 1016
2020
Q2 		$301K Sell
20,313
-12,043
-37% -$183K ﹤0.01% 1601
2020
Q1 		$355K Buy
+32,356
New +$304K 0.01% 1212
2019
Q1 		– Sell
-18,601
Closed -$83K – 2415
2018
Q4 		$83K Buy
18,601
+6,303
+51% +$34.6K ﹤0.01% 1814
2018
Q3 		$99K Buy
+12,298
New +$87.7K ﹤0.01% 1886
2018
Q1 		– Sell
-10,216
Closed -$89K – 2110
2017
Q4 		$89K Buy
+10,216
New +$101K ﹤0.01% 1972

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Squarepoint's SNDX Position: Q2 2026 in Review

Squarepoint increased its Syndax Pharmaceuticals (SNDX) stake by 104% in Q2 2026, buying an estimated $3.93M and bringing the position to 370,317 shares worth $8.1M. The position accounts for 0.01% of the portfolio, ranked #1243.

Squarepoint first reported a position in SNDX in Q4 2017 and has held it in 17 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Squarepoint held 370,317 shares of Syndax Pharmaceuticals worth $8.1M as of Q2 2026.
  • Squarepoint bought 188,765 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.93M.
  • Syndax Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1243 holding.
  • Squarepoint first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 17 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.